1. Scrip
  2. >>Business

Merck & Co. CEO Davis Debuts With A Leaner Organization And Money To Spend

 
• By Jessica Merrill

Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.

Deals Sign
Merck's new CEO outlined his business development strategy • Source: Alamy

Merck & Co., Inc..'s new CEO Robert Davis made his public debut as the company's leader during its second quarter sales and earnings call on 29 July. The leadership transition represents a new start for the company in multiple ways, as this is also the first quarter for Merck as a substantially leaner organization, having spun out its established products, biosimilars and women's health portfolio under the Organon moniker.

"I know it's not about promising. It's about performing. Actions speak louder than words," Davis said, opening the call with...

More from Earnings

More from Business

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.